<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Drug doses for oral treatment of hypertension in pregnancy</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Drug doses for oral treatment of hypertension in pregnancy</h1>
<div class="graphic"><div class="figure"><div class="ttl">Drug doses for oral treatment of hypertension in pregnancy</div><div class="cntnt"><table cellspacing="0"><colgroup span="6" width="16%"></colgroup> <tbody> <tr> <td class="subtitle1">Drug</td> <td class="subtitle1">Class</td> <td class="subtitle1">Initial dose</td> <td class="subtitle1">Usual effective dose range</td> <td class="subtitle1">Maximum suggested total daily dose</td> <td class="subtitle1">Comments</td> </tr> <tr> <td>Labetalol</td> <td>Combined alpha and beta blocker</td> <td>100 mg 2 times daily, increase by 100 mg twice daily every 2 to 3 days as needed</td> <td>200 to 800 mg in 2 divided doses</td> <td>2400 mg</td> <td> <p>Can cause bronchoconstriction. Avoid in patients with asthma, chronic obstructive lung disease, heart failure, bradycardia (heart rate &lt;60 beats per minute), or greater than first-degree heart block.</p> The dosing interval can be increased to 3 times daily if blood pressure is increased prior to the next prescribed dose.</td> </tr> <tr> <td> <p>Hydralazine</p> <strong>NOTE:</strong> Due to reflex tachycardia, monotherapy with oral hydralazine is not recommended; hydralazine may be combined with methyldopa or labetalol if needed as add-on therapy</td> <td>Peripheral vasodilator</td> <td>Begin with 10 mg 4 times per day, increase by 10 to 25 mg/dose every 2 to 5 days</td> <td>50 to 100 mg in 2 to 4 divided doses</td> <td>200 mg*</td> <td> </td> </tr> <tr> <td>Nifedipine extended release (ER)<sup>¶</sup></td> <td>Calcium channel blocker</td> <td>30 to 60 mg once daily as an extended release tablet, increase at 7 to 14 day intervals</td> <td>30 to 90 mg once daily</td> <td>120 mg</td> <td> <p>Do not administer sublingually.</p> Based upon clinical experience of UpToDate contributors, some patients better tolerate nifedipine ER administered in 2 divided doses, which may serve to minimize its peak to trough effects (eg, instead of increasing the dose to 60 mg once daily, it may be desirable in some patients to increase to 30 mg 2 times daily).</td> </tr> <tr> <td>Methyldopa</td> <td>Centrally acting alpha agonist</td> <td>250 mg 2 to 3 times daily, increase every 2 days as needed<sup>Δ</sup></td> <td>250 to 1000 mg in 2 to 3 divided doses</td> <td>3000 mg</td> <td>Sedation is a common side effect.</td> </tr> </tbody></table></div><div class="graphic_footnotes"><p>* Chronic hydralazine doses above 100 mg daily are associated with an increased risk for developing lupus erythematosus, particularly in females and slow acetylators; ascertainment of acetylator status is recommended before increasing dose above 100 mg per day in many countries.</p>
<p>¶ UpToDate suggests not using immediate-release nifedipine (oral or sublingual) because it can cause significant rapid decreases in blood pressure. If used, the dose is 10 to 20 mg every 2 to 6 hours, with a maximum daily dose of 180 mg.</p>
Δ The full hypotensive effect of an initial dose or adjustment of methyldopa may not occur until after 2 to 3 days of continuous use.</div><div class="graphic_reference">Adapted from:
<ol>
<li>Seely EW, Ecker J. Chronic hypertension in pregnancy. N Engl J Med 2011; 365:439.</li>
<li>Magee LA. Treating hypertension in women of child-bearing age and during pregnancy. Drug Saf 2001; 24:457.</li>
</ol></div><div id="graphicVersion">Graphic 55212 Version 19.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
